EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Prehospital tirofiban increases the rate of disrupted myocardial infarction in patients with ST-segment elevation myocardial infarction: insights from the On-TIME 2 trial

Sem A O F Rikken iD, Enrico Fabris iD, Tobias Rosenqvist iD, Evangelos Giannitsis iD, Jurriën M Ten Berg, Christian Hamm iD, Arnoud van 't Hof iD

European Heart Journal: Acute Cardiovascular Care · 2024

DOI: 10.1093/ehjacc/zuae074 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Heart Journal: Acute Cardiovascular Care, 2024. Verfasst von Sem A O F Rikken und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. Hauptthemen laut MEDLINE: Tirofiban, ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention, Emergency Medical Services. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

In patients with ST-segment elevation myocardial infarction (STEMI), prehospital tirofiban significantly improved myocardial reperfusion. However, its impact on the rate of disrupted myocardial infarction (MI), particularly in the context of high-sensitivity cardiac troponin (hs-cTn) assays, is still unclear. Methods and results The On-TIME 2 (Ongoing Tirofiban In Myocardial infarction Evaluation 2) trial randomly assigned STEMI patients to prehospital tirofiban or placebo before transportation to a percutaneous coronary intervention (PCI) centre. In this post hoc analysis, we evaluated STEMI patients that underwent primary PCI and had measured hs-cTn levels. Troponin T levels were collected at 18–24 and 72–96 h after PCI. Disrupted MI was defined as peak hs-cTn T levels ≤ 10 times the upper limit of normal (≤140 ng/L). Out of 786 STEMI patients, 47 (6%) had a disrupted MI. Disrupted MI occurred in 31 of 386 patients (8.0%) in the tirofiban arm and in 16 of 400 patients (4.0%) in the placebo arm (P = 0.026). After multivariate adjustment, prehospital tirofiban remained independently associated with disrupted MI (odds ratio 2.03; 95% confidence interval 1.10–3.87; P = 0.027). None of the patients with disrupted MI died during the 1-year follow-up, compared with a mortality rate of 2.6% among those without disrupted MI.

Conclusion

Among STEMI patients undergoing primary PCI, the use of prehospital tirofiban was independently associated with a higher rate of disrupted MI. These results, highlighting a potential benefit, underscore the need for future research focusing on innovative pre-treatment approaches that may increase the rate of disrupted MI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TirofibanST Elevation Myocardial InfarctionPercutaneous Coronary InterventionEmergency Medical ServicesHumansMaleFemaleMiddle AgedAgedTyrosineTroponin TPlatelet Aggregation InhibitorsTreatment OutcomeDouble-Blind MethodElectrocardiography

Stichwörter der Autor:innen

Disrupted myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrehospitalSTEMITirofiban

Substanzen

TirofibanTyrosineTroponin TPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
  • Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
  • Cardiothoracovascular Department, University of Trieste, Trieste, Italy.
  • Department of Cardiology, Zuyderland Medical Center, Heerlen, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands.
  • Department of Cardiology, Universitaetsklinik, Heidelberg, Germany.
  • Department of Cardiology, Maastricht University Medical Center, P. Debyelaan 25 | 6229 HX Maastricht, Locatie: MUMC+, Level 3, Postbus 5800 | 6202 AZ Maastricht, The Netherlands.

ORCID-Profile: Sem A O F Rikken, Enrico Fabris, Tobias Rosenqvist, Evangelos Giannitsis, Christian Hamm, Arnoud van 't Hof

Zitieren

APA

Rikken, S. A. O. F., Fabris, E., Rosenqvist, T., Giannitsis, E., Ten Berg, J. M., Hamm, C., & van 't Hof, A. (2024). Prehospital tirofiban increases the rate of disrupted myocardial infarction in patients with ST-segment elevation myocardial infarction: insights from the On-TIME 2 trial. European Heart Journal: Acute Cardiovascular Care. https://doi.org/10.1093/ehjacc/zuae074

Vancouver

Rikken SAOF, Fabris E, Rosenqvist T, Giannitsis E, Ten Berg JM, Hamm C, et al. Prehospital tirofiban increases the rate of disrupted myocardial infarction in patients with ST-segment elevation myocardial infarction: insights from the On-TIME 2 trial. European Heart Journal: Acute Cardiovascular Care. 2024. doi:10.1093/ehjacc/zuae074

BibTeX
@article{Rikken2024,
  author = {Rikken, Sem A O F and Fabris, Enrico and Rosenqvist, Tobias and Giannitsis, Evangelos and Ten Berg, Jurriën M and Hamm, Christian and van 't Hof, Arnoud},
  title = {Prehospital tirofiban increases the rate of disrupted myocardial infarction in patients with ST-segment elevation myocardial infarction: insights from the On-TIME 2 trial},
  journal = {European Heart Journal: Acute Cardiovascular Care},
  year = {2024},
  doi = {10.1093/ehjacc/zuae074}
}
Kostenlos starten →